<DOC>
	<DOCNO>NCT01145170</DOCNO>
	<brief_summary>The study consist one treatment group , receive first-line therapy disease - standard radiotherapy 150 mg/m2 dose investigational product ( nimotuzumab )</brief_summary>
	<brief_title>Nimotuzumab Radiotherapy Pediatric Patients With Glioma</brief_title>
	<detailed_description>General Purpose 1 . To determine therapeutic efficacy treatment nimotuzumab combination radiotherapy pediatric patient diffuse intrinsic astrocytic brainstem glioma Specific Purposes 1 . To determine efficacy regard event-free survival ( EFS ) rate 6 month treatment . 2 . To determine overall survival time patient diffuse intrinsic astrocytic tumor cerebral trunk treat combined radiotherapy nimotuzumab . 3 . To determine antitumoral objective response patient treat combined radiotherapy nimotuzumab . 4 . To determine duration time response case objective response reach ( CR PR ) disease stabilization . 5 . To assess toxicity combination AcM h-R3-nimotuzumab radiotherapy patient enrol clinical study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Pediatric patient diffuse intrinsic brainstem glioma , document standard image technique ( MRI ) . Note : Tumor biopsy histological confirmation require study . 2 . Patients eligible radiotherapy Cobalt60 . The patient receive previous specific oncological treatment . 3 . Aged &gt; 3 year old &lt; 18 year old 4 . Patients measurable lesion , define accurately measure least 2 dimension ( 2 large perpendicular diameter ) , use standard technique ( MRI ) . 5 . Female patient childbearing potential present negative pregnancy test adopt effective birth control method , case sexually active . 6 . Male patient father child adopt effective birth control method , case sexually active . 7 . Life expectancy &gt; 12 week 8 . Health general status , accord Karnofsky Index &gt; 40 % ( Karnofsky Index patient &gt; 16 year old ) , Lansky &gt; 40 % ( patient &lt; 16 year old ) 9 . Laboratory parameter within normal limit , define : Hematopoietic : Hemoglobin &gt; 10 g/L , Total Leukocytes &gt; 2 x 109 cells/L , Platelets &gt; 100 x 109/L ; Hepatic : Liver function within normal limit without hepatic disease demonstrate ALT , AST &lt; 2.5 x reference value Total Bilirubin &lt; 1.5 x reference value ; Renal function : Serum Creatinine &lt; 1.5 x reference value . 10 . The parent legal guardian express , voluntarily , write , patient enrol study upon signature inform consent form . At investigator 's discretion , applicable , consent obtain minor . 1 . Lowgrade brainstem glioma ( e.g. , focal , cervicomedullary , tectal brainstem glioma ) . 2 . Patients previously treat AcM . 3 . Patients previously treat antineoplastic therapy , include chemotherapy , immunotherapy radiotherapy . 4 . Concurrent treatment antineoplastic therapy conceive study protocol . 5 . Breastfeeding pregnant patient . 6 . Patients , time enrollment , relate chronic disease decompensation ( e.g. , cardiopathy , diabetes , hypertension ) . 7 . Patients history hypersensitivity another similar product . 8 . Fever , severe septic process and/or severe acute allergy . 9 . Patients participate another clinical study therapeutic purpose disease base time study enrollment . 10 . Presence second tumor .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>brainstem glioma</keyword>
	<keyword>pediatric patient</keyword>
</DOC>